Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + Ixazomib + Dexamethasone in non-t(11;14) RRMM
NCT03856112Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Jun 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of venetoclax in multiple myeloma (MM), sponsored by National Cancer Institute. Planned start Jun 2019; status: withdrawn.
02
Drugs
venetoclax
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03856112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03856112.